(RTTNews) - Tenaya Therapeutics, Inc. (TNYA) announced the FDA has granted Regenerative Medicine Advanced Therapy designation to TN-401, Tenaya's gene therapy candidate for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Tenaya's RMAT application included data presented at the American Society for Gene and Cell Therapy Annual Meeting in May 2026. Faraz Ali, CEO of Tenaya Therapeutics, said: "We look forward to sharing additional data from RIDGE-1 in the fourth quarter and providing an update on our ongoing discussions with regulators regarding pivotal trial plans for TN-401." In pre-market trading on NasdaqCM, Tenaya shares are down 0.30 percent to $0.6381. For More Such Health News, visit rttnews.com.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.